Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/SYRE
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Spyre Therapeutics Inc. Common Stock (SYRE) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Read full analysis

Key Stats

  • Market Cap
    $7.52B
  • Volume
    1,441,031
  • Sector
    Health
  • 52W High
    $108.92
  • 52W Low
    $22.18
  • Typical Hold Time
    0 Days
  • Enterprise Value
    $6.52B
  • Div Yield
    -
  • Trading Activity
    0% Sell | 100% Buy
$78.63
52W Low: $22.18
10 Nov 2025
52W High: $108.92
19 Aug 2026

Track Spyre Therapeutics Inc. Common Stock (SYRE) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Spyre Therapeutics Inc. Common Stock has traded between a low of $22.18 and a high of $108.92, highlighting its annual price range. Buy and sell Spyre Therapeutics Inc. Common Stock shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Spyre Therapeutics Inc. Common Stock

Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.

Most Recent News

Content is generated by Aura AI

Apple's revenue quadrupled to $416B under Tim Cook, driven by iPhone sales soaring to $210B.

Over 15 years as CEO, Tim Cook led Apple to grow its annual revenue from $108 billion to $416 billion, with iPhone sales alone increasing from $47 billion to nearly $210 billion. This remarkable growth highlights Apple's strong market position and in...

Market News
41 minutes ago
Jeremy Bowman
Bullish
news icon
Apple's revenue quadrupled to $416B under Tim Cook, driven by iPhone sales soaring to $210B.

Global leaders gather in Singapore to explore AI, tokenization, and digital assets reshaping capital markets

The fourth Digital Assets & Tokenization Summit held in Singapore brought together global financial leaders, institutional investors, and tech innovators to discuss how AI, tokenization, and digital assets are transforming capital markets. Key discus...

Market News
4 hours ago
Luna Pr
Neutral
Global leaders gather in Singapore to explore AI, tokenization, and digital assets reshaping capital markets

Apple's revenue quadrupled to $416B under Tim Cook, driven by soaring iPhone sales.

Over Tim Cook's 15-year tenure as Apple's CEO, the company's annual revenue grew from $108 billion to $416 billion, with iPhone sales increasing from $47 billion to nearly $210 billion. This remarkable growth highlights Apple's strong market position...

Market News
4 hours ago
The Motley Fool
Bullish
news icon
Apple's revenue quadrupled to $416B under Tim Cook, driven by soaring iPhone sales.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $7.52B
  • Volume
    1,441,031
  • Sector
    Health
  • 52W High
    $108.92
  • 52W Low
    $22.18
  • Typical Hold Time
    0 Days
  • Enterprise Value
    $6.52B
  • Div Yield
    -
  • Trading Activity
    0% Sell | 100% Buy
$78.63
52W Low: $22.18
10 Nov 2025
52W High: $108.92
19 Aug 2026

Track Spyre Therapeutics Inc. Common Stock (SYRE) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Spyre Therapeutics Inc. Common Stock has traded between a low of $22.18 and a high of $108.92, highlighting its annual price range. Buy and sell Spyre Therapeutics Inc. Common Stock shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!